natgillin/translations-raw huggingface dataset:
No dose adjustment is necessary for patients with mild or moderate renal impairment (CLcr equal or greater than 30 ml/min), as shown in study BM 16549 where the majority of patients had mild to moderate renal impairment. 
Za bolnike z blago ali zmerno ledvično okvaro (očistek kreatinina (CLcr) enak ali večji kot 30 ml/min) prilagajanje odmerkov ni potrebno, kar se je pokazalo v študiji BM 16549, kjer je večina bolnikov imela blažjo do zmerno ledvično okvaro.
In the overall patient population of the study MF4411, no reduction was observed for non-vertebral fractures, however daily ibandronic acid appeared to be effective in a high-risk subpopulation (femoral neck BMD T-score < -3.0), where a non-vertebral fracture risk reduction of 69% was observed. 
V celotni populaciji bolnikov v študiji MF4411 niso opazili zmanjšanja nevretenčnih zlomov, ugotovili pa so, da je bila ibandronska kislina enkrat na dan učinkovita pri podskupini bolnikov z visokim tveganjem (T-vrednost MKG stegneničnega vratu pod -3,0), kjer se je tveganje za nevretenčne zlome zmanjšalo za 69 %.
If you have been told by your doctor that you cannot tolerate or digest some sugars (e.g. if you have a galactose intolerance, the Lapp lactase deficiency or have problems with glucose-galactose absorption), talk to your doctor before taking this medicine. 
Če vam je zdravnik povedal, da ne prenašate ali prebavljate nekaterih sladkorjev (npr. ne prenašate galaktoze, imate laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze), se z njim posvetujte, preden vzamete to zdravilo.
The recommended dose is one 150 mg film-coated tablet once a month. 
Priporočeni odmerek je ena 150-mg filmsko obložena tableta na mesec.
Adequate intake of calcium and vitamin D is important in all patients. 
Zadosten vnos kalcija in vitamina D je pomemben za vse bolnike.
The concentration of ibandronic acid in the solution for injection is 1mg per ml. 
Koncentracija ibandronske kisline v raztopini za injiciranje je 1 mg na ml.
Please consult your doctor - if you are allergic to ibandronic acid or any of the other ingredients of this medicine (listed in section 6). 
posvetujte se z zdravnikom; - če ste alergični na ibandronsko kislino ali katero koli sestavino tega zdravila (navedeno v poglavju 6.
Do not take Bondenza - If you are allergic to ibandronic acid, or any of the other ingredients of this medicine listed in section 6). 
Ne jemljite zdravila Bondenza - Če ste alergični na ibandronsko kislino ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Do not receive Bondenza - if you have, or had in the past, low blood calcium. 
Ne prejemajte zdravila Bondenza: - če imate znižano koncentracijo kalcija v krvi, ali ste jo imeli v preteklosti.
Bondenza, like other bisphosphonates administered intravenously, may cause a transient decrease in serum calcium values. 
Zdravilo Bondenza lahko, tako kot drugi difosfonati, ki jih dajemo intravensko, povzroči prehodno zmanjšanje serumskih vrednosti kalcija.
The histological analysis of bone biopsies after two and three years of treatment of postmenopausal women showed bone of normal quality and no indication of a mineralization defect. 
Histološka analiza biopsij kosti po dveh in treh letih zdravljenja žensk v postmenopavzi je pokazala normalno kakovost kosti in odsotnost motenj mineralizacije.
Missed dose: 
Izpuščeni odmerek:
- Water is the only drink that should be taken with Bondenza. 
- Voda je edina tekočina, ki jo lahko bolnik zaužije z zdravilom Bondenza.
Bondenza may help lower the chances of breaking bones (fractures). 
Zdravilo Bondenza pomaga zmanjšati možnost zloma.
Bondenza 3 mg solution for injection in pre-filled syringe must not be mixed with calcium-containing solutions (such as Ringer-Lactate solution, calcium heparin) or other intravenously administered medicinal products. 
Zdravila Bondenza 3 mg raztopina za injiciranje v napolnjeni injekcijski brizgi ne smemo mešati z raztopinami, ki vsebujejo kalcij (kot je raztopina Ringerjevega laktata, kalcijev heparin) ali drugimi intravensko dajanimi zdravili.
Patients with a previous history of gastrointestinal disease including patients with peptic ulcer without recent bleeding or hospitalisation, and patients with dyspepsia or reflux controlled by medication were included in the once monthly treatment study. 
Bolniki z anamnezo bolezni prebavil, vključno s peptično razjedo brez nedavne krvavitve ali hospitalizacije, dispepsijo ali refluksom, urejenim z zdravili, so bili vključeni v študijo z odmerjanjem enkrat na mesec.
Gender Pharmacokinetics of ibandronic acid are similar in men and women. 
Spol Farmakokinetika ibandronske kisline je pri moških in ženskah podobna.
What you need to know before you take Bondenza 
Kaj morate vedeti, preden boste vzeli zdravilo Bondenza
Elderly population (>65 years) No dose adjustment is required (see section 5.2). 
Starejši bolniki (>65 let) Prilagajanje odmerkov ni potrebno (glejte poglavje 5.2).
- If you are under dental treatment or will undergo dental surgery, tell your dentist that you are being treated with Bondenza. 
- Pred zdravljenjem bolezni ali operacijo zob povejte svojemu zobozdravniku, da se zdravite z zdravilom Bondenza.
In addition, 64.8 % of patients receiving 3 mg every 3 months injection were identified as responders (defined as a decrease ≥50 % from baseline), compared with 64.9 % of patients receiving 2.5 mg daily orally. 
Poleg tega je bilo 64,8 % bolnikov, ki so prejemali 3-mg injekcijo vsake 3 mesece, odzivnih (odzivnost so definirali kot ≥ 50-% zmanjšanje od izhodišča) v primerjavi s 64,9 % bolnikov, ki so prejemali 2,5 mg na dan peroralno.
The usual dose of Bondenza is one tablet once a month. 
Običajen odmerek zdravila Bondenza je ena tableta enkrat na mesec.
The recommended dose of Bondenza for the intravenous injection is 3 mg (1 pre-filled syringe) once every 3 months. 
Priporočeni odmerek zdravila Bondenza za intravensko injiciranje je 3 mg (1 napolnjena injekcijska brizga) vsake 3 mesece.
In vivo, ibandronic acid prevents experimentally induced bone destruction caused by cessation of gonadal function, retinoids, tumours or tumour extracts. 
In vivo ibandronska kislina preprečuje eksperimentalno povzročeno razgradnjo kosti zaradi prenehanja delovanja žlez, retinoidov, tumorjev ali ekstraktov tumorjev.
Protein binding in human plasma is approximately 85 % - 87 % (determined in vitro at therapeutic concentrations), and thus there is a low potential for interaction with other medicinal products due to displacement. 
Vezava na plazemske beljakovine pri ljudeh je približno 85- do 87-% (določeno in vitro pri terapevtskih koncentracijah), zato je medsebojno delovanje z drugimi zdravili zaradi izpodrivanja malo verjetno.
Contains 162.75 mg lactose monohydrate (equivalent to 154.6 mg anhydrous lactose). 
Pomožne snovi z znanim učinkom: vsebuje 162,75 mg laktoze monohidrata (enakovredno 154,6 mg brezvodne laktoze).
- If you have, or had in the past low blood calcium. 
- Če imate znižano koncentracijo kalcija v krvi, ali ste jo imeli v preteklosti.
Existing hypocalcaemia must be corrected before starting Bondenza therapy. 
Obstoječo hipokalcemijo je treba popraviti pred začetkom zdravljenja z zdravilom Bondenza.
The incidence of clinical vertebral fractures was also significantly reduced by 49 % (p=0.011). 
Incidenca kliničnih zlomov vretenc je bila značilno zmanjšana za 49 % (p = 0,011).
Milk or antacids should be given to bind Bondenza, and any adverse reactions treated symptomatically. 
Za vezavo zdravila Bondenza je treba zaužiti mleko ali antacide, neželene učinke pa zdravimo simptomatično.
Bondenza tablets are white to off white, of oblong shape and marked “BNVA” on one side, and “150” on the other side. 
Bondenza tablete so bele do sivo bele barve, podolgovate oblike z oznako “BNVA” na eni strani in “150” na drugi strani.
Bondenza contains less than 1 mmol sodium (23 mg) per dose (3 ml), i.e. essentially “sodiumfree”. 
Zdravilo Bondenza vsebuje manj kot 1 mmol (23 mg) natrija na odmerek (3 ml), kar v bistvu pomeni ‛brez natrija'.
No specific information is available on the treatment of overdose with Bondenza. 
Specifičnih informacij o zdravljenju prevelikega odmerjanja zdravila Bondenza ni na voljo.
The tablets are supplied in blisters containing 1 or 3 tablets. 
Na voljo so v pretisnih omotih v pakiranju po 1 ali 3 tablete.
How to take Bondenza). 
Kako jemati zdravilo Bondenza).
A clinically meaningful reduction of 50 % of biochemical markers of bone resorption was observed as early as one month after start of treatment with ibandronic acid 2.5 mg. 
Klinično pomembno 50-% zmanjšanje biokemičnih označevalcev kostne resorpcije so opazili že en mesec po začetku zdravljenja z 2,5 mg ibandronske kisline.
Pre-filled syringes (5 ml) made of colourless type I glass, the grey rubber plunger stopper and tip cap are made of fluororesin-laminated butyl rubber, containing 3 ml of solution for injection. 
Napolnjene injekcijske brizge (5 ml) so iz brezbarvnega stekla tipa I, siv gumijast zamašek bata in zaporka pa sta iz s fluororesinom laminirane gume; vsebujejo 3 ml raztopine za injiciranje.
If your next scheduled dose is only 1 to 7 days away… You should wait until the next scheduled dose is due and take it as normal; then, continue taking one tablet once a month on the scheduled days you've marked on your calendar. 
Če je do vašega načrtovanega odmerka le 1 do 7 dni… počakajte do naslednjega načrtovanega odmerka in ga vzemite kot običajno, nato jemanje tablet nadaljujte enkrat na mesec, na izbrane dni, ki ste si jih označili na koledarju.
One year data in study BM 16549 Two year data in study BM 16549 
Dveletni podatki iz študije BM 16549
NAME OF THE MEDICINAL PRODUCT Bondenza 150 mg film-coated tablets 
IME ZDRAVILA Bondenza 150 mg filmsko obložene tablete
Bondenza should not be used during breastfeeding. 
Zdravila Bondenza se med dojenjem ne sme uporabljati.
Patients with cardiac impairment Overhydration should be avoided in patients at risk of cardiac failure. 
Bolniki s srčno okvaro Pri bolnikih, pri katerih obstaja tveganje za srčno popuščanje, se je treba izogibati pretirani hidraciji.
The pharmacokinetics of ibandronic acid in these patients is unknown, and ibandronic acid should not be used under these circumstances. 
Ker je farmakokinetika ibandronske kisline pri tej skupini bolnikov neznana, ibandronske kisline pri njih ne smemo uporabljati.
Biochemical markers of bone turnover (such as urinary CTX and serum Osteocalcin) showed the expected pattern of suppression to premenopausal levels and reached maximum suppression within a period of 3-6 months. 
Biokemični označevalci kostne premene (kot so urinarni CTX in serumski osteokalcin) so pokazali pričakovan vzorec supresije do vrednosti pred menopavzo, največjo supresijo so dosegli po 3 do 6 mesecih.
In studies with daily i.v. 
Samo za i.v.
Because of these possible irritant effects and a potential for worsening of the underlying disease, caution should be used when Bondenza is given to patients with active upper gastrointestinal problems (e.g. known Barrett's oesophagus, dysphagia, other oesophageal diseases, gastritis, duodenitis or ulcers). 
Zaradi možnih dražečih učinkov ter možnega poslabšanja predhodne bolezni je treba zdravilo Bondenza pri bolnikih z aktivnimi obolenji zgornjega dela prebavil (npr. potrjenim Barrettovim požiralnikom, disfagijo, drugimi boleznimi požiralnika, gastritisom, duodenitisom ali razjedami) uporabljati previdno.
Any unused solution for injection, syringe and injection needle should be disposed of in accordance with local requirements. 
Neuporabljeno raztopino za injiciranje, brizge in injekcijske igle zavrzite v skladu z lokalnimi predpisi.
- The other ingredients are sodium chloride, acetic acid, sodium acetate trihydrate and water for injections. 
- Pomožne snovi so natrijev klorid, ocetna kislina, natrijev acetat trihidrat in voda za injekcije.
What Bondenza looks like and contents of the pack 
Izgled zdravila Bondenza in vsebina pakiranja
If your next scheduled dose is more than 7 days away… You should take one tablet the next morning after the day you remember; then, continue taking one tablet once a month on the scheduled days you've marked on your calendar. 
Če je vaš načrtovani odmerek čez več kot 7 dni… vzemite eno tableto naslednje jutro potem, ko se spomnite, nato jemanje tablet nadaljujte enkrat na mesec, na izbrane dni, ki ste si jih označili na koledarju.
The overall proportion of patients who experienced an adverse reaction, was 22.7 % and 25.0 % for Bondenza 150 mg once monthly after one and two years, respectively. 
Celoten delež bolnikov, pri katerih se je pojavil neželeni učinek, je bil 22,7 % za zdravilo Bondenza 150 mg enkrat na mesec po enem letu in 25,0 % po dveh letih.
While no increased risk was observed in controlled clinical trials there have been post-marketing reports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications. 
Čeprav v okviru nadzorovanih kliničnih preskušanj niso opazili povečanega tveganja pri uporabi peroralnih difosfonatov, so v obdobju po prihodu na trg poročali o razjedah želodca in dvanajstnika; nekateri primeri so bili hudi in z zapleti.
Early plasma levels fall quickly, reaching 10 % of the peak values within 3 and 8 hours after intravenous or oral administration, respectively. 
Zgodnje plazemske koncentracije hitro padejo, 10 % največje vrednosti dosežejo 3 ure po intravenskem dajanju in 8 ur po peroralnem dajanju.
Bondenza solution for injection must not be mixed with calcium-containing solutions or other intravenously administered medicinal products. 
Zdravila Bondenza, raztopine za injiciranje, ne smemo mešati z raztopinami, ki vsebujejo kalcij, ali drugimi intravensko dajanimi zdravili.
The absorbed fraction of ibandronic acid is removed from the circulation via bone absorption (estimated to be 40-50 % in postmenopausal women) and the remainder is eliminated unchanged by the kidney. 
Absorbiran delež ibandronske kisline se iz sistemskega krvnega obtoka v kostno tkivo odstrani z absorpcijo (ocenjeno na 40 do 50 % pri ženskah v postmenopavzi), ostanek pa se izloči skozi ledvice v nespremenjeni obliki.
Studies in lactating rats have demonstrated the presence of low levels of ibandronic acid in the milk following intravenous administration. 
Študije pri podganah v laktaciji so pokazale, da je po intravenskem dajanju v mleku prisotna majhna količina ibandronske kisline.
After 2 years of treatment, 92.8 % of patients receiving 
Po dveh letih je bilo odzivnih 78,7 % bolnikov
Medicinal product-Food Interaction 
Medsebojno delovanje med zdravilom in hrano
Bondenza contains lactose. 
Zdravilo Bondenza vsebuje laktozo.
Patients with hepatic impairment No dose adjustment is required (see section 5.2). 
Bolniki z jetrno okvaro Prilagajanje odmerkov ni potrebno (glejte poglavje 5.2).
Talk to your doctor before receiving Bondenza: - If you have or have ever had kidney problems, kidney failure or have needed dialysis, or if you have any other disease that may affect your kidneys 
Preden boste prejeli zdravilo Bondenza se posvetujte s svojim zdravnikom: - če imate ali ste kdaj imeli težave z ledvicami, oslabljeno ledvično delovanje, ste potrebovali dializo ali pa imate katerokoli drugo bolezen, ki lahko vpliva na ledvice; - če imate kakršne koli motnje presnove mineralov (kot je pomanjkanje vitamina D).
Renal clearance of ibandronic acid in patients with various degrees of renal impairment is linearly related to creatinine clearance. 
Renalni očistek ibandronske kisline pri bolnikih z različnimi stopnjami ledvične okvare je v linearni odvisnosti od kreatininskega očistka.
The liver has no significant role in the clearance of ibandronic acid, which is not metabolised but is cleared by renal excretion and by uptake into bone. 
Jetra niso pomembna za očistek ibandronske kisline, ker se ne presnavlja, ampak izloča z renalno ekskrecijo in vstopanjem v kostno tkivo.
White to off white film-coated tablets, of oblong shape marked “BNVA” on one side, and “150” on the other side. 
Filmsko obložene tablete so bele do sivo bele barve, podolgovate oblike z oznako “BNVA” na eni strani in “150” na drugi strani.
All patients must receive adequate supplemental calcium and vitamin D. 
Vsi bolniki morajo prejemati ustrezne dodatke kalcija in vitamina D.
Other things that can increase the risk of fractures include: - not enough calcium and vitamin D in the diet - smoking, or drinking too much alcohol - not enough walking or other weight-bearing exercise - a family history of osteoporosis 
Drugi dejavniki, ki lahko povečajo tveganje za zlome, so: - premajhen vnos kalcija in vitamina D s hrano, - kajenje ali čezmerno pitje alkohola, - pomanjkanje hoje ali drugih telesnih aktivnosti, - družinska obremenjenost z osteoporozo.
Some people need to be especially careful while they're taking Bondenza. 
Nekateri ljudje morajo biti pri jemanju zdravila Bondenza še posebno previdni.
Bioavailability is reduced by about 90 % when ibandronic acid is administered with a standard breakfast in comparison with bioavailability seen in fasted subjects. 
Pri sočasnem jemanju ibandronske kisline s standardnim zajtrkom se biološka uporabnost zmanjša za okoli 90 % v primerjavi z biološko uporabnostjo, ki so jo opazili pri bolnikih po postu.
PEEL-OFF STICKERS FOR YOUR PERSONAL CALENDAR Monthly tablet 
NALEPKE ZA VAŠ OSEBNI KOLEDAR Mesečna tableta Mesečna tableta Mesečna tableta Bondenza
Bondenza 3 mg intravenous injection, administered every 3 months, was shown to be at least as effective as oral ibandronic acid 2.5 mg daily in a 2-year, randomised, double-blind, multicentre, noninferiority study (BM16550) of postmenopausal women (1386 women aged 55 - 80) with osteoporosis (lumbar spine BMD T-score below -2.5 SD at baseline). 
Zdravilo Bondenza v obliki 3-mg intravenske injekcije, ki se daje vsake 3 mesece, se je izkazalo za najmanj enako učinkovito kakor ibandronska kislina 2,5 mg enkrat na dan peroralno v dveletni randomizirani, dvojno slepi, multicentrični, neinferiorni študiji (BM 16550) pri ženskah z osteoporozo v postmenopavzi (1.386 žensk, starih 55 do 80 let z izhodiščno T-vrednostjo MKG ledvene hrbtenice pod -2,5 SD).
1 pre-filled syringe + 1 injection needle 4 pre-filled syringes + 4 injection needles 
1 napolnjena injekcijska brizga + 1 injekcijska igla 4 napolnjene injekcijske brizge + 4 injekcijske igle
- not enough calcium and vitamin D in the diet - smoking cigarettes, or drinking too much alcohol - not enough walking or other weight-bearing exercise - a family history of osteoporosis 
- premajhen vnos kalcija in vitamina D s hrano, - kajenje cigaret ali čezmerno pitje alkohola, - pomanjkanje hoje ali drugih telesnih aktivnosti, - družinska obremenjenost z osteoporozo.
Ibandronic acid leads to progressive net gains in bone mass and a decreased incidence of fractures through the reduction of elevated bone turnover towards premenopausal levels in postmenopausal women. 
Ibandronska kislina povzroči progresivno čisto povečanje kostne mase in zmanjša incidenco zlomov, tako da pri ženskah v postmenopavzi zmanjša povečano razmerje med razgradnjo in tvorbo kosti in ga približa razmerju pred menopavzo.
After one year (primary analysis) the median relative change from baseline was -76 % for Bondenza 150 mg once monthly and -67 % for ibandronic acid 2.5 mg daily. 
Po enem letu (primarna analiza) je bila mediana relativne spremembe od izhodiščne vrednosti -76 % za zdravilo Bondenza 150 mg enkrat na mesec in -67 % za ibandronsko kislino 2,5 mg enkrat na dan.
Osteonecrosis of jaw*† 
osteonekroza čeljustnic*†
- If you have certain problems with your gullet/food pipe (oesophagus) such as narrowing or difficulty swallowing. 
- Če imate določene težave s požiralnikom, kot je zožitev ali težave s požiranjem.
How to receive Bondenza 
Kako prejemati zdravilo Bondenza
There are no data on the effects of ibandronic acid from humans. 
O vplivu ibandronske kisline pri ljudeh ni podatkov.
Bondenza 150 mg film-coated tablets Ibandronic acid 
Bondenza 150 mg filmsko obložene tablete ibandronska kislina
Based on the results of study BM 16549, Bondenza 150 mg once monthly is expected to be at least as effective in preventing fractures as ibandronic acid 2.5 mg daily. 
Glede na rezultate študije BM 16549 pričakujemo, da je zdravilo Bondenza 150 mg enkrat na mesec najmanj enako učinkovito v preprečevanju zlomov kakor ibandronska kislina 2,5 mg enkrat na dan.
Planning when to take Bondenza with peel-off stickers for your personal calendar What Bondenza is and what it is used for What you need to know before you take Bondenza How to take Bondenza 
Kaj vsebuje navodilo Načrtovanje jemanja zdravila Bondenza z nalepkami za vaš osebni koledar Kaj je zdravilo Bondenza in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Bondenza Kako jemati zdravilo Bondenza Možni neželeni učinki 5 Shranjevanje zdravila Bondenza Vsebina pakiranja in dodatne informacije
Bondenza is available in packs of 1 pre-filled syringe and 1 injection needle or 4 pre-filled syringes and 4 injection needles. 
Bondenza je na voljo v pakiranju po 1 napolnjeno injekcijsko brizgo in 1 injekcijsko iglo ali po 4 napolnjene injekcijske brizge in 4 injekcijske igle.
ibandronic acid 2.5 mg administered daily, showed a statistically significant and medically relevant reduction in the incidence of new vertebral fractures. 
Dajanje 2,5 mg ibandronske kisline na dan je povzročilo statistično značilno in klinično pomembno zmanjšanje incidence novih zlomov vretenc.
If the next scheduled dose is within 7 days, patients should wait until their next dose and then continue taking one tablet once a month as originally scheduled. 
Če je do naslednjega načrtovanega odmerka manj kot 7 dni, naj bolnik počaka do tega odmerka in nadaljuje jemanje ene tablete enkrat na mesec po prvotnem načrtu.
Table 2: Mean relative change from baseline of lumbar spine, total hip, femoral neck and trochanter BMD after one year (primary analysis) and two years of treatment (Per-Protocol Population) in study BM 16549. 
Preglednica 2: Povprečna relativna sprememba od izhodiščne vrednosti MKG ledvene hrbtenice, kolka, femoralnega vratu in trohantra po enem letu (primarna analiza) in dveh letih zdravljenja (populacija po protokolu) v študiji BM 16549.
The absorption of ibandronic acid in the upper gastrointestinal tract is rapid after oral administration and plasma concentrations increase in a dose-proportional manner up to 50 mg oral intake, with greater than dose-proportional increases seen above this dose. 
Po peroralnem jemanju je absorpcija ibandronske kisline v zgornjem delu gastrontestinalnega trakta hitra, plazemske koncentracije naraščajo do peroralnega vnosa 50 mg v odvisnosti od odmerka, pri večjih vnosih pa so opazili večje poraste plazemskih koncentracij od sorazmernih z odmerkom.
Due to the limited clinical experience, Bondenza is not recommended in patients with severe renal impairment (see section 4.2 and section 4.4) . 
Zaradi omejenih kliničnih izkušenj jemanje zdravila Bondenza pri bolnikih s hudo okvaro ledvic ni priporočljivo (glejte poglavje 4.2 in poglavje 4.4).
Bondenza 3 mg injection every 3 months (N=365) 
Bondenza 3 mg v obliki injekcije vsake 3 mesece (n = 365)
If you are breast-feeding, you will need to stop breast-feeding in order to receive Bondenza. 
Če dojite, boste morali z dojenjem prenehati, da bi lahko prejemali zdravilo Bondenza.
The study enrolled women aged 55 to 80 years, who were at least 5 years postmenopausal, who had a BMD at lumbar spine of 2 to 5 SD below the premenopausal mean (T-score) in at least one vertebra [L1-L4], and who had one to four prevalent vertebral fractures. 
Študija je vključevala ženske, stare od 55 do 80 let, ki so bile vsaj 5 let v postmenopavzi in ki so imele MKG ledvene hrbtenice 2 do 5 SD pod povprečno vrednostjo pred menopavzo (T-vrednost) pri vsaj enem vretencu (L1-L4) ter so imele enega do štiri predhodnih zlomov vretenc.
Existing hypocalcaemia must be corrected before starting Bondenza injection therapy. 
Obstoječo hipokalcemijo je treba popraviti pred začetkom zdravljenja z zdravilom Bondenza v obliki injekcije.
Trochanter BMD 
MKG trohantra